Breast Cancer Microvesicles as a Novel Plasma Biomarker and Therapeutic Target (IDEA)
Abstract
The current report is the final report for this project. We received a no-cost extension on this project until 4/2010. Funding on this project ceased on 4/1/10. We still have clinical specimens and are anxious to resume testing on these. We are currently applying for VA and NIH funding for this purpose. If we do get funded to continue, we will notify the DOD via the U.S. Army Medical Research and Materiel Command at Fort Detrick, Maryland. This project proposed to develop a clinical assay for tumor microvesicles (MV) from the blood of patients with breast cancer. This assay was applied to test the hypothesis that the level of plasma tumor MV predict response to treatment and subsequent relapse in patients with locally advanced breast cancer. We and others have shown that tumor MV can express HER-2 protein. Thus, we also proposed to use this assay to determine if trastuzumab is able to clear tumor MV from the blood of breast cancer patients.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2010
- Accession Number
- ADA548619
Entities
People
- Kevin Harris
Organizations
- University of Alabama